Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
26/03/2026 06:00
Mar 26 (Reuters) - Innate Pharma FY EPS continuing operations EUR -0.55. FY adjusted operating income EUR -54.008 million FY operating income EUR -54.008 million FY basic EPS EUR -0.55 FY net income continuing operations EUR -49.177 million
Recent news on Innate Pharma SA
See all newsBrief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member